{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T05:09:21Z","timestamp":1779167361236,"version":"3.51.4"},"reference-count":11,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>This article reports a case of bilateral renal subcapsular hemorrhage in a 51-year-old female patient with lung adenocarcinoma and multiple metastases after receiving four cycles of combination antitumor therapy with pemetrexed, carboplatin, sintilimab, and bevacizumab. The patient had a pre-existing cystic lesion in the right kidney and developed intermittent fever, hypertension, and anemia during treatment. The diagnosis was confirmed by a renal contrast-enhanced CT scan. Management involved immediate discontinuation of bevacizumab, absolute bed rest, hemostasis, antihypertensive therapy, and other comprehensive treatments. The renal hemorrhage was effectively controlled and gradually resolved. Based on the temporal relationship of medication use and clinical manifestations, the renal hemorrhage was considered to be associated with bevacizumab. In recent years, bevacizumab has been widely used in tumor treatment; however, its adverse effects still require further exploration. Hemorrhage induced by bevacizumab primarily occurs in the respiratory tract, digestive tract, and brain, while renal subcapsular hemorrhage has not been reported. This case suggests that bleeding manifestations caused by bevacizumab are diverse and remain a cause for vigilance.<\/jats:p>","DOI":"10.3389\/fonc.2026.1804964","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T04:22:55Z","timestamp":1779164575000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A case report of bevacizumab-induced subcapsular renal hemorrhage in a patient with lung adenocarcinoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Yue","family":"Du","sequence":"first","affiliation":[{"name":"Xinhua Hospital, Dalian University","place":["Liaoning, Dalian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Yu","sequence":"additional","affiliation":[{"name":"Xinhua Hospital, Dalian University","place":["Liaoning, Dalian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei-Yan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Xinhua Hospital, Dalian University","place":["Liaoning, Dalian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Xu","sequence":"additional","affiliation":[{"name":"Xinhua Hospital, Dalian University","place":["Liaoning, Dalian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang-Hua","family":"Song","sequence":"additional","affiliation":[{"name":"2nd Tumor Ward, Xinhua Hospital, Dalian University","place":["Liaoning, Dalian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: A review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.06.012","article-title":"Molecular landscape and therapeutic strategies of lung cancer lineage plasticity","volume":"20","author":"Banerjee","year":"2025","journal-title":"J Thorac Oncol Off Publ Int Assoc For Study Lung Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000001479","article-title":"Comparative investigation of neoadjuvant immunotherapy versus adjuvant immunotherapy in perioperative patients with cancer: A global-scale, cross-sectional, and large-sample informatics study","volume":"110","author":"Guo","year":"2024","journal-title":"Int J Surg (London England)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102237","article-title":"Adenocarcinoma spectrum lesions of the lung: Detection, pathology and treatment strategies","volume":"99","author":"Succony","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5070\/d330564427","article-title":"Bevacizumab-induced subungual hemorrhage","volume":"30","author":"Owen","year":"2024","journal-title":"Dermatol Online J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2248876","article-title":"A pharmacovigilance study of adverse event profiles and haemorrhagic safety of bevacizumab based on the FAERS database","volume":"23","author":"Tang","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.idcr.2022.e01490","article-title":"Renal subcapsular hematoma with abscess in severe COVID-19","volume":"28","author":"Takahashi","year":"2022","journal-title":"IDCases"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2023.09.005","article-title":"Immunoregulation mechanism of VEGF signaling pathway inhibitors and its efficacy on the kidney","volume":"366","author":"Li","year":"2023","journal-title":"Am J Med Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34332","article-title":"Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis","volume":"152","author":"Gu","year":"2023","journal-title":"Int J Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1681\/asn.20233411s1782c","article-title":"Frequency and characteristics of chemotherapy-associated thrombotic microangiopathy: Analysis from a large pharmacovigilance database","volume":"98","author":"Klomjit","year":"2023","journal-title":"Am J Hematol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.3390\/cells10113146","article-title":"Molecular mechanisms of hypertensive nephropathy: Renoprotective effect of losartan through Hsp70","volume":"10","author":"Costantino","year":"2021","journal-title":"Cells"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1804964\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T04:22:55Z","timestamp":1779164575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1804964\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":11,"alternative-id":["10.3389\/fonc.2026.1804964"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1804964","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"article-number":"1804964"}}